| Company Name: |
BOC Sciences |
| Tel: |
16314854226; +8616314854226 |
| Email: |
inquiry@bocsci.com |
|
| | Clazakizumab Basic information |
| Product Name: | Clazakizumab | | Synonyms: | Clazakizumab;Research Grade Clazakizumab(DHC15805);Research Grade Clazakizumab;Clazakizumab (anti-IL-6) | | CAS: | 1236278-28-6 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Clazakizumab Structure]() |
| | Clazakizumab Chemical Properties |
| | Clazakizumab Usage And Synthesis |
| Uses | Clazakizumab is a monoclonal antibody with high affinity and specificity for the IL-6 (interleukin-6) cytokine. Clazakizumab may be helpful in inhibiting the cytokine response to SARS-CoV-2 in COVID-19. Clazakizumab can be used for the research of psoriatic arthritis (PsA) and renal antibody-mediated rejection[1][2]. | | IC 50 | IL-6 | | References | [1] Mease PJ, et al. The Efficacy and Safety of Clazakizumab, an Anti-Interleukin-6 Monoclonal Antibody, in a Phase IIb Study of Adults With Active Psoriatic Arthritis. Arthritis Rheumatol. 2016 Sep;68(9):2163-73. DOI:10.1002/art.39700
[2] Vaidya G, et al. Successful Treatment of Severe COVID-19 Pneumonia With Clazakizumab in a Heart Transplant Recipient: A Case Report. Transplant Proc. 2020 Nov;52(9):2711-2714. DOI:10.1016/j.transproceed.2020.06.003 |
| | Clazakizumab Preparation Products And Raw materials |
|